歌礼制药-B：截至二零二五年十二月三十一日止年度之年度业绩公告及所得款项用途变动

(i) ASC30GLP-17.7%III(ii) ASC30GLP-113II(iii) ASC30GLP-1(depot)13(lead-in)167.5%(depot)(observed half-life)4675ASC304(iv) ASC47THRβ2956.2%ASC4740ASC35II(v) ASC39eloralintideFDAASC39IND(vi) ASC36FDAASC36IND(vii) ASC36FDAASC36IND(viii) ASC35GLP-1R/GIPRFDAASC35IND(ix) ASC36ASC35GLP-1R/GIPRFDAASC36_35 FDCIND(x) ASC37GLP-1R/GIPR/GCGRFDAASC37IND(xi)ASC36ASC37GLP-1R/GIPR/GCGRFDAASC36_37 FDCIND(xii) ASC50 IL-17A104IL-17AASC50710600ASC50(dose-proportional)SADASC50(xiii)(ASC40)FASN12(ASC40)33.2%14.6%(ASC40)57.4%35.4%(ASC40)63.5%43.2%ASC40III(ASC40)IIIIIIASC40 1,932.61,980.8 302.435.3%409.1300.919.6%359.9 35.3%19.6%(i)(ii)(iii) 1.SagimetASC40 GLP-1R-1GIPRGCGRTHRββIL-17-17FASN ASC30 GLP-1RASC3013II(NCT07002905)125BMI≥30.0 kg/m²BMI≥27.0 kg/m² ASC3013ASC302040605.4%7.0%7.7% 80.0%60ASC30≥5%4.2%45.0%60ASC30≥7%4.2% ASC30ASC30(LDL-C)ASC30 (titrated weekly)ASC30orforglipronASC30orforglipronIIIATTAIN-1(titrated everyfourweeks)ASC30II(AE)123ASC30II3(SAE)(ALT)(AST)(TBL)QTc IIASC30 ASC30GLP-1RASC30(NCE) ASC30III ASC30 GLP-1RASC30213II(NCT07321678) II10022:3:3:2406080ASC30ASC301(titrated weekly)406080 ASC3013II ASC30 GLP-1RASC30II24(NCT06679959)65A1A2BMI ≥ 30 kg/m²27 kg/m² ≤ BMI ≤ 30 kg/m² II3ASC30A112p<0.056.3%ASC30A11316p<0.057.5% A S C 3 0A 11 2I b( N C T 0 6 6 7 9 9 5 9 )4 67 5A1( t h e r a p e u t i cd r u gexposures) ASC30A1ASC30A11294578400ASC30A14812162.7%5.5%6.3%7.5% ASC304 ASC30A1816ASC30A11685.5%2036.4%2445.8% ASC30A1A2GLP1ASC30A1A2(AE)(GI)12QTc ASC30(lead-in)4GLP-1 ASC30ASC30 ASC30 ASC47 ASC47 29ASC47BMI≥30 kg/m²56.2% ASC47-103(NCT06972992)ASC470.5(volume-matched)0.54628ASC471030600.528ASC47 ASC47ASC47ASC47 ASC47ASC47ASC476.7%57.1%(TSH)(FT3)(TT3)(FT4)(TT4)TEAE(telemetry)(ECG)QTc (titration)TEAE THRβASC4756.2%II ASC47ASC35II ASC39 ASC39 eloralintide(cAMP)ASC39eloralintideASC39eloralintide1(hAMY1R)EC5021.4pM21.2pMASC39eloralintide(hCTR)EC50846.1 pM1,350.8 pMhCTRASC39eloralintidehAMY1R eloralintide(DIO)ASC39eloralintideASC396.6%eloralintide5.6% FDAASC39IND ASC36 ASC36 (NHP)ASC36MET-233i6 DIOASC36petrelintide91% ASC36pH(nofibrillationaround neutral pH)GLP-1R/GIPRASC35 FDAASC36IND ASC36 ASC36 (POTENT)ASC366%8% ASC36116167 ASC36713.2%ASC36 DIO7eloralintidepetrelintideASC3632%91% ASC36ASC36 ASC36AIArtificial Intelligence-assistedStructure-Based Drug DiscoveryAISBDDASC36POTENT FDAASC36IND ASC35 GLP-1R/GIPRASC35 (NHP)ASC35146 ASC3580%70% GLP-1RGIPR4 DIOASC3571% FDAASC35IND ASC36_35 FDC ASC36GLP-1R/GIPRASC35 ASC36GLP-1R/GIPRASC35ASC36ASC35(ULAP) DIOASC36eloralintide32%DIOASC3571% DIOASC36ASC35eloralintide51% DIOASC36ASC35MET-233i47%eloralintide98% ASC36ASC35pH FDAASC36_35FDCIND ASC37 GLP-1R/GIPR/GCGRASC37 (NHP)ASC37156 G L P - 1 RG I P RG C G RA S C 3 7retatrutide12116 FDAASC37IND IL-17ASC50 I(NCT07024602)(SAD)ASC50IL-17A 1030100200400600ASC50(elimination half-life)4389 91 87 10485 ASC50IL-17AASC507 10600ASC50(dose-proportional) LY4100511DC-853IL-17ASC50 SADASC50(AE)1(SAE) ASC50 ASC50IL-17IL-17ASC50(NCE)2043 ASC50(MAD) (ASC40) FASN(ASC40)III(NCT06192264)III(NCT06248008)(ASC40)(NMPA) III(NCT06192264)(ASC40)4801:150(ASC40)12(ASC40) FASN(ASC40)12(ASC40)33.2%14.6%p <0.0001(ASC40)57.4%35.4%p <0.0001(ASC40)63.5%43.2%p <0.000112(ASC40)51.9%28.9%p <0.0001 50(ASC40)12(ASC40)(TEAE)TEAE10%TEAE5%(ASC40)6.3%2.9%(ASC40)5.9%3.8%(ASC40)(AE)(ASC40)34(ASC40)(SAE) (ASC4018.6%)(FDA)sarecycline9.4%doxycycline6.7%98%178% (ASC4018.6%)FDA(clascoterone)(11.6%)60% III(NCT06248008)(ASC40)24024040(ASC40)12(ASC40) (ASC40)(TEAE)12(ASC40)34AE(ASC40)SAE (ASC40)(1)(DNL)(2)Th17(ASC40)(ASC40) (ASC40)IIIIII NMPA(ASC40)(NDA) (i)AI(AISBDD)(ii)(ULAP)(iii)(POTENT) 18A.05 17,000 10 1.ASC30III 2.ASC3013II 3.ASC30 ASC47ASC35II 5.FDAASC39IND 6.FDAASC36IND FDAASC36IND 8.FDAASC35IND 9.FDAASC36_35 FDCIND10.FDAASC37IND11.FDAASC36_37 FDCIND12.ASC50(MAD)13.NMPA(ASC40)(NDA)14.15. 121.1127.4 119.84.6%125.3(i)22.7SagimetSagimet1.7(ii)SagimetSagimet24.524.5(iii)21.137.321.1Sagimet 101.726.1%75.2 (i)(ii)(iii) 302.435.3%409.1 0.20.2 11.893.4%0.8 1 1. 0.5 4.457.1%1.9 1,8744,3731,8744,373 0.2 3090 9.19.1%9.9 1.2184.0%3.5 53.556.4 7.426.1 1,344311,34431 1,344311,34431 66.069.4 45.730.6 13.717.2 15.34.011.2 416.8421.24.4 662.2580.1 345.2428.0 2.032.0%1.3 (a)Viking Viking Therapeutics, Inc.VikingASC41ASC43FITCUSDC ITCITCASC41ASC43F1930337567,0004,038,000 USDCVikingUSDC (b) 25(i)(ii)(iii) 0.60.6 (1)15.112.9(2)15.012.8(3)6.4%7.5% (1)(2)(3)100% 12.915.112.815.0 7.5%6.4% 20220180.2% 188.1136.1 7.06.4 4,6695,357 1,934,2641,966,162 1 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, CaymanIslands 2 (a) 2(c) (b) 2 (c) 21 3 (a) 15 (ii) 1 0 %Sagimet Biosciences Inc.Sagimet20.2%Northridge Health Group (HongKong) Co., LimitedNorthridge79.8% 1 0 %Sagimet Biosciences Inc.Sagimet53.1%Northridge46.9% (iii) 1 5121(a) 3 (b) (c) (i)(ii) (i)(ii)Sagimet 5 (a) 5(c) 1,50154810,89212,1074,7324,6771,9933,6701,8001,800234122i409